The market for non-steroidal anti-inflammatory drugs (NSAIDs) encompasses a broad range of oral and topical formulations designed to relieve pain, reduce inflammation, and lower fever. Key products include traditional NSAIDs such as ibuprofen and naproxen, as well as selective COX-2 inhibitors like celecoxib. These agents offer distinct advantages over corticosteroids and opioids, including a lower risk of central nervous system dependency, shorter onset of action, and fewer serious systemic side effects when used appropriately. Non-Steroidal Anti-Inflammatory Drugs Market are indispensable for managing conditions such as osteoarthritis, rheumatoid arthritis, musculoskeletal injuries, and acute postoperative pain. Their over-the-counter availability in many regions has further boosted patient accessibility and compliance, while prescription-strength formulations cater to chronic and severe inflammatory disorders. Innovation in drug delivery—such as extended-release tablets, transdermal patches, and topical gels—has improved dosing convenience and localized effect, minimizing gastrointestinal exposure. As healthcare systems grapple with rising incidences of chronic pain and inflammatory diseases, the demand for effective, cost-efficient anti-inflammatory therapies continues to grow.

According to CoherentMI, The non-steroidal anti-inflammatory drugs market is estimated to be valued at USD 25.84 Bn in 2025 and is expected to reach USD 38.60 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.9% from 2025 to 2032.

Get More Insight On:  Non-Steroidal Anti-Inflammatory Drugs Market

Get this Report in Japanese Language: 非ステロイド性抗炎症薬市場

Get this Report in Korean Language: 비스테로이드성항염제시장